

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Milvexian
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BMS-986177 (milvexian) is an investigational, oral factor XIa (FXIa) inhibitor (antithrombotic) which delays the time to clot formation, decreases fibrin incorporation into the clot, and reduces the resistance of clots to fibrinolysis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 25, 2023
Lead Product(s) : Milvexian
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Milvexian
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
Details : Milvexian is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Atrial Fibrillation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 07, 2023
Lead Product(s) : Milvexian
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Milvexian
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
Details : Milvexian is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Acute Coronary Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 06, 2023
Lead Product(s) : Milvexian
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Milvexian
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BMS-986177 (milvexian) is an investigational, oral factor XIa (FXIa) inhibitor (antithrombotic) which delays the time to clot formation, decreases fibrin incorporation into the clot, and reduces the resistance of clots to fibrinolysis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 02, 2023
Lead Product(s) : Milvexian
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Milvexian,Midazolam,Ethinyl Estradiol,Drospirenone
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Milvexian in Healthy Adult Females
Details : Milvexian is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 31, 2023
Lead Product(s) : Milvexian,Midazolam,Ethinyl Estradiol,Drospirenone
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Milvexian
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Milvexian is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Ischemic Stroke.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 27, 2023
Lead Product(s) : Milvexian
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Milvexian
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : JNJ-70033093 (milvexian) is a potential first-in-class oral factor XIa (FXIa) inhibitor (anti-thrombotic) being studied for the prevention and treatment of major thrombotic conditions.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 28, 2022
Lead Product(s) : Milvexian
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Milvexian
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase II
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Milvexian demonstrated efficacy and no increase in bleeding across doses, when compared with enoxaparin, for postoperative venous thromboembolism (VTE) prevention in patients undergoing elective total knee replacement (TKR) surgery.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 15, 2021
Lead Product(s) : Milvexian
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase II
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Milvexian,14-C BMS-986177
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BMS-986177 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 16, 2021
Lead Product(s) : Milvexian,14-C BMS-986177
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Milvexian
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participants
Details : Milvexian is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 14, 2021
Lead Product(s) : Milvexian
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
